Randomized clinical trials in rectal and anal cancer

Aviram Nissan, Michael I. D'Angelica, Margo C. Shoup, John E. Hartley, David P. Jagues*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Treatment of rectal cancer has changed dramatically over the past two decades. Radical surgery alone for resectable rectal cancer has been replaced by combined modality therapy. Interest in optimizing sphincter preservation and quality of life motivated surgeons to seek less radical surgery without compromising oncologic principles. The treatment of advanced colorectal cancer has long been a dilemma for clinicians. After many years of therapy limited to 5-fluorouracil (5-FU)-based chemotherapy, a number of new discoveries have significantly advanced this field in the last decade. The advent of irinotecan has given us hope for a second line chemotherapeutic agent and a possible new combination for first line chemotherapy.

Original languageEnglish (US)
Pages (from-to)149-172
Number of pages24
JournalSurgical Oncology Clinics of North America
Volume11
Issue number1
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Randomized clinical trials in rectal and anal cancer'. Together they form a unique fingerprint.

Cite this